Casdin Partners Master Fund, L.P. bought LAB

August 13, 2025 · Form 4 insider transaction

Casdin Partners Master Fund, L.P. bought 75,000 shares of Standard BioTools Inc. at $1.31 per share, a transaction worth $98.3K. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Acquired (buy-side)
Shares
75,000
Price
$1.31
Total value
$98.3K
Role—
SecurityCommon Stock
Transaction codeP: Open-market purchase
Transaction dateAugust 13, 2025
Filing dateAugust 15, 2025
Shares owned after59,466,780
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.3075 to $1.3118. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.; The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.

View the original Form 4 on SEC EDGAR